Equity Profile

ORKA

Oruka Therapeutics, Inc.

Health CareBiotechnology$5.1B

May13Wed

Post-Earnings Recap

ReportedQ1-2026After Close4:03 PM EDT

Oruka Therapeutics Misses Revenue, Stock Down 2.27%

Metric	Actual	Expected	Surprise
EPS	$-0.48	$-0.54	+8.40%
Revenue	$0M	$0M	—

management commentary, guidance changes, and full analysis available with Pro.

Oruka Therapeutics Misses Revenue, Stock Down 2.27%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.48	$-0.54	+8.40%
Revenue	$0M	$0M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Oruka Therapeutics reported a narrower loss per share than expected, which is a positive sign for investors. However, the stock fell by 2.27%, indicating that investors may have been disappointed by the lack of revenue and guidance. The absence of management commentary also leaves some uncertainty about the company's future direction.

Company Snapshot

Oruka Therapeutics, Inc. operates in the biotechnology sector, focusing on developing innovative therapies for various health conditions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.54

Revenue

While no revenue is expected this quarter, any updates on future revenue streams will be critical for investor confidence.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Oruka Therapeutics, Inc. operates in the biotechnology sector, focusing on developing innovative therapies for various health conditions. With a market cap of $4 billion, the company plays a crucial role in advancing healthcare solutions, particularly in areas that may lack effective treatments.

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

In the last quarter, Oruka reported an EPS of $-0.45, which was better than the expected $-0.61, leading to a slight decline in stock price. The company has not provided specific revenue figures, which has left investors cautious.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Oruka to report a loss this quarter, but there is hope for a smaller loss than previously anticipated. Investors are looking for any signs of progress in the company's pipeline.

Bull Case

If Oruka can report a smaller loss than expected and provide positive updates on its drug development, it could boost investor confidence and lead to a stock price increase.

Bear Case

If the company fails to meet EPS expectations or provides no clear path to future revenue, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.54

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams will be critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.54?

This will be crucial for gauging the company's financial health and investor sentiment going forward.

Are there any updates on the drug pipeline that could indicate future revenue potential?

Investors are keen to understand the company's growth prospects, especially given the lack of expected revenue this quarter.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Oruka's drug pipeline to yield results sooner than expected, leading to a quicker recovery in EPS.

Supporting Evidence

The company has consistently beaten EPS estimates in the past, indicating a potential for another surprise.

Options pricing suggests a larger move than historical averages, hinting at investor uncertainty that could swing positively.

Key Risk

If the company can provide a clear timeline for drug development, it could significantly alter the market's perception.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Oruka can maintain its positive surprise trend while also addressing its revenue potential.

Bull Confirmed If

An EPS of $-0.46 or better would confirm a positive outlook for the company.

Bear Confirmed If

An EPS worse than $-0.65 would signal deeper issues within the company.

Pre-Earnings Positioning

Options Market

Implied Move

±7.39%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move following the earnings report, indicating uncertainty among investors.

Options are pricing ±7.4% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

78.0%

Calls (10K)P/C Ratio: 17.67Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats EPS expectations, history suggests a potential average move of +2.56%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline, with historical patterns suggesting an average move of -2.33%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug pipeline and expected timelines for results.
2Management's commentary on cost management and operational efficiency.
3Insights into potential partnerships or collaborations that could enhance revenue.
4Discussion of market conditions and how they may impact future growth.
5Any guidance on expected future revenue streams or product launches.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

RadNet, Inc.

Company Snapshot

Oruka Therapeutics, Inc. operates in the biotechnology sector, focusing on developing innovative therapies for various health conditions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.54

Revenue

While no revenue is expected this quarter, any updates on future revenue streams will be critical for investor confidence.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Oruka to report a loss this quarter, but there is hope for a smaller loss than previously anticipated. Investors are looking for any signs of progress in the company's pipeline.

Bull Case

If Oruka can report a smaller loss than expected and provide positive updates on its drug development, it could boost investor confidence and lead to a stock price increase.

Bear Case

If the company fails to meet EPS expectations or provides no clear path to future revenue, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.54

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams will be critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.54?

This will be crucial for gauging the company's financial health and investor sentiment going forward.

Are there any updates on the drug pipeline that could indicate future revenue potential?

Investors are keen to understand the company's growth prospects, especially given the lack of expected revenue this quarter.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Oruka's drug pipeline to yield results sooner than expected, leading to a quicker recovery in EPS.

Supporting Evidence

The company has consistently beaten EPS estimates in the past, indicating a potential for another surprise.

Options pricing suggests a larger move than historical averages, hinting at investor uncertainty that could swing positively.

Key Risk

If the company can provide a clear timeline for drug development, it could significantly alter the market's perception.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Oruka can maintain its positive surprise trend while also addressing its revenue potential.

Bull Confirmed If

An EPS of $-0.46 or better would confirm a positive outlook for the company.

Bear Confirmed If

An EPS worse than $-0.65 would signal deeper issues within the company.

Pre-Earnings Positioning

Options Market

Implied Move

±7.39%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move following the earnings report, indicating uncertainty among investors.

Options are pricing ±7.4% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

78.0%

Calls (10K)P/C Ratio: 17.67Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats EPS expectations, history suggests a potential average move of +2.56%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline, with historical patterns suggesting an average move of -2.33%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug pipeline and expected timelines for results.
2Management's commentary on cost management and operational efficiency.
3Insights into potential partnerships or collaborations that could enhance revenue.
4Discussion of market conditions and how they may impact future growth.
5Any guidance on expected future revenue streams or product launches.